Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients who are ≥18 years old~* Diagnosed with ESRD and are stable on hemodialysis for more than 3 months~* Maintained stable Hgb for ≥4 weeks prior to screening~* Two consecutive Hgb values ≥10.5 g/dL within 5 weeks of screening~* Body mass index (BMI) between 18 kg/m2 and 42 kg/m2, inclusive, based upon the latest height and weight~* Ferritin levels ≥100 mg/L or Tsat ≥20% or reticulocyte hemoglobin content (CHr) \>25 at screening~* Reasonable clearances on dialysis (KT/V ≥1.0) on two prior determinations within 2.5 months~* Able to provide written informed consent~* Able to understand and follow all trial procedures~* Willing to use contraception as detailed in the protocol~Exclusion Criteria:~* Hgb remains unchanged without erythropoietin (\<0.5 g/dL decrease during the 8 week maximum erythropoietin-washout period)~* Receipt of iron infusion after the initiation of erythropoietin washout~* Receipt of red blood cell transfusion within four weeks before screening~* Overt gastrointestinal bleeding or other bleeding episode that required transfusion within 2 months prior to screening~* Infection necessitating antibiotic or anti-viral treatment within a month prior to screening~* Requirement for Coumadin (warfarin), Pradaxa or Xarelto~* Hemoglobinopathies such as homozygous sickle-cell disease or thalassemias of all types~* Active hemolysis or chronic hypoxia~* Active malignant diseases (except non-melanoma skin cancer) or life expectancy less than 6 months~* Chronic, uncontrolled or symptomatic inflammatory disease or non-renal cause of anemia such as rheumatoid arthritis, systemic lupus erythematosus, HIV, or systemic acute infection~* On immunosuppressive therapeutics~* Chronic congestive heart failure (New York Heart Association Class III, IV)~* Significant hypertension (≥90 diastolic) based on a sitting diastolic blood pressure at screening~* Kidney transplant within the past year: patients who are off immunosuppressive agents following a failed transplant are eligible for the trial~* End-stage liver disease~* Known hypersensitivity to recombinant protein therapies~* Female patients who are pregnant or breast feeding~* Previous exposure to FMX-8~* Exposure to Omontys® or Hematide® (peginesatide) anemia treatment within the past 6 months~* Treatment with Aranesp® (darbepoetin alpha) within the past 4 weeks~* Uncontrolled hyperparathyroidism (PTH \>750) based upon latest PTH determination within the past 4 months~* Inability to comply with the trial scheduled visits

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FMX-8 (0.5 mg/kg) (Type: EXPERIMENTAL): 0.5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
- FMX-8 (5 mg/kg) (Type: EXPERIMENTAL): 5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
- FMX-8 (15 mg/kg) (Type: EXPERIMENTAL): 15 mg/kg FMX-8 IV twice per week for 29 days (9 doses)

Based on this trial design, predict the completion outcome and termination type (if applicable).